BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...degradation-focused biotechs have launched since 2018.Three —Amphista Therapeutics Ltd....
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...Medicines Corp. Monte Rosa Therapeutics Inc. Ranok Therapeutics Co. Ltd. Amphista Therapeutics Ltd. Janpix...
BioCentury | Aug 22, 2020
Emerging Company Profile

Amphista: broadening the target space of protein degradation

...Dundee, where Founder and Director Alessio Ciulli serves as chair of chemical and structural biology.While Amphista Therapeutics Ltd....
...million ($8.6 million) Investors: Advent Life Sciences, Scottish Investment Bank and BioMotivCEO: Nicola ThompsonPatents: None issued Danielle Golovin Amphista Therapeutics Ltd. University...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

...was head of global specialty clinical development at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). Amphista Therapeutics Ltd....
...in the firm’s soon-to-be-opened San Francisco office. Robin Sawka, BioCentury Staff Asklepios BioPharmaceutical Inc. Seer Inc. Meridian Biopharmaceuticals Liquidia Technologies Inc. Amphista Therapeutics Ltd. Science...
BioCentury | Apr 9, 2020
Finance

April 8 Quick Takes: Amphista’s series A; Invitae, Fudan-Zhangjiang and MedGenome

...Scottish protein degradation company raises series A Amphista Therapeutics Ltd. raised $7.5 million in a series A round...
Items per page:
1 - 5 of 5
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...degradation-focused biotechs have launched since 2018.Three —Amphista Therapeutics Ltd....
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...Medicines Corp. Monte Rosa Therapeutics Inc. Ranok Therapeutics Co. Ltd. Amphista Therapeutics Ltd. Janpix...
BioCentury | Aug 22, 2020
Emerging Company Profile

Amphista: broadening the target space of protein degradation

...Dundee, where Founder and Director Alessio Ciulli serves as chair of chemical and structural biology.While Amphista Therapeutics Ltd....
...million ($8.6 million) Investors: Advent Life Sciences, Scottish Investment Bank and BioMotivCEO: Nicola ThompsonPatents: None issued Danielle Golovin Amphista Therapeutics Ltd. University...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

...was head of global specialty clinical development at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). Amphista Therapeutics Ltd....
...in the firm’s soon-to-be-opened San Francisco office. Robin Sawka, BioCentury Staff Asklepios BioPharmaceutical Inc. Seer Inc. Meridian Biopharmaceuticals Liquidia Technologies Inc. Amphista Therapeutics Ltd. Science...
BioCentury | Apr 9, 2020
Finance

April 8 Quick Takes: Amphista’s series A; Invitae, Fudan-Zhangjiang and MedGenome

...Scottish protein degradation company raises series A Amphista Therapeutics Ltd. raised $7.5 million in a series A round...
Items per page:
1 - 5 of 5